Jennifer L. Taubert
Net Worth

Last updated:

What is Jennifer L. Taubert net worth?

The estimated net worth of Ms. Jennifer L. Taubert is at least $59,648,753 as of 13 Feb 2024. She owns shares worth $25,248,413 as insider, has earned $22,880,340 from insider trading and has received compensation worth at least $11,520,000 in Johnson & Johnson.

What is the salary of Jennifer L. Taubert?

Ms. Jennifer L. Taubert salary is $1,920,000 per year as Executive Vice President & Worldwide Chairman of Pharmaceuticals in Johnson & Johnson.

How old is Jennifer L. Taubert?

Ms. Jennifer L. Taubert is 61 years old, born in 1964.

What stocks does Jennifer L. Taubert currently own?

As insider, Ms. Jennifer L. Taubert owns shares in one company:

Company Title Shares Price per share Total value
Johnson & Johnson (JNJ) Executive Vice President & Worldwide Chairman of Pharmaceuticals 141,416 $178.54 $25,248,413

What does Johnson & Johnson do?

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

JNJ logo
JNJ
Johnson & Johnson
$178.54

Jennifer L. Taubert insider trading

Johnson & Johnson

Ms. Jennifer L. Taubert has made 2 insider trades between 2019-2024, according to the Form 4 filled with the SEC.

The largest trade she's ever made was exercising 76,923 units of JNJ stock on 22 Nov 2022. As of 13 Feb 2024 she still owns at least 141,416 units of JNJ stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Share Units 1,302 N/A N/A
Option
Common Stock 1,302 N/A N/A
Option
Common Stock 22,433 N/A N/A
Option
Common Stock 3,769 N/A N/A
Option
Performance Share Units 22,433 N/A N/A
Option
Common Stock 59,397 $90.44 $5,371,865
Sale
Common Stock 59,397 $156.27 $9,281,969
Option
Employee Stock Options (Right to Buy) 59,397 $90.44 $5,371,865
Option
Common Stock 3,739 N/A N/A
Option
Restricted Share Units 3,739 N/A N/A
Option
Common Stock 3,570 N/A N/A
Option
Restricted Share Units 3,570 N/A N/A
Option
Employee Stock Options (Right to Buy) 76,923 $72.54 $5,579,994
Option
Common Stock 76,923 $72.54 $5,579,994
Sale
Common Stock 76,923 $176.78 $13,598,371
Option
Performance Share Units 18,064 N/A N/A
Option
Common Stock 18,064 N/A N/A
Option
Common Stock 3,297 N/A N/A
Option
Restricted Share Units 3,297 N/A N/A
Option
Common Stock 13,606 N/A N/A
Option
Common Stock 13,606 N/A N/A
Option
Performance Share Units 11,429 N/A N/A
Option
Common Stock 16,084 N/A N/A
Option
Performance Share Units 8,360 N/A N/A
Option
Common Stock 48,312 N/A N/A
Option
Restricted Share Units 48,312 N/A N/A
Option
Common Stock 9,748 N/A N/A
Option
Performance Share Units 9,748 N/A N/A
Option
Restricted Share Units 8,529 N/A N/A
Option
Common Stock 8,529 N/A N/A

Johnson & Johnson key executives

Johnson & Johnson executives and other stock owners filed with the SEC: